[Dostinex (cabergoline)- a significant advance in prolactin control].
Tomov
I
I
D000284:Administration, Oral; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004873:Ergolines / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy*; D007986:Luteinizing Hormone / Q000187:drug effects*; D017448:Receptors, Dopamine D2 / Q000187:drug effects; D013997:Time Factors; D016896:Treatment Outcome
D018491:Dopamine Agonists; D004873:Ergolines; D017448:Receptors, Dopamine D2; D007986:Luteinizing Hormone; D000077465:Cabergoline